Dr. Hollinger has been actively involved in hepatitis research since joining the Department of Molecular Virology and Microbiology at Baylor College of Medicine in Houston, Texas in 1968 and the Department of Medicine (GI Section) in 1981. He is currently Professor of Medicine, Molecular Virology & Epidemiology and Director of the Eugene B. Casey Hepatitis Research Center. He also serves as Clinical Investigator/Sub-Investigator for Advanced Liver Therapies at Baylor St. Luke's Medical Center. He has been an advisor and consultant on program projects, grants, and contracts related to viral hepatitis for the National Institutes of Health and the Food and Drug Administration (FDA) and is a consultant to the Transfusion Transmitted Diseases Committee (TTD) of the American Association of Blood Banks (AABB) involved in the monitoring of emerging infectious disease agents that represent a potential threat to transfusion safety. He served on the Blood Products Advisory Committee (BPAC) for the FDA from 1995-2000, becoming its Chairman in 1997, and in 2009 accepted a reappointment to BPAC as its chairman until 2012.
Dr. Hollinger is an experienced researcher, hepatologist and international speaker who has engaged in a number of national, multicenter clinical trials and basic scientific projects related to viral hepatitis over the past 35 years. He has published over 265 peer-reviewed articles, books and chapters in the field of liver disease that includes the characterization and diagnosis of viral hepatitis agents, development of sensitive immunological assays, prophylaxis of hepatitis A and B including vaccine development, therapy of hepatitis B and C, studies on the immunopathogenesis and natural history of viral hepatitis, and the epidemiology of blood-borne pathogens and posttransfusion hepatitis.